Empaglif lozin as Add-On to Metformin in Patients With Type 2 Diabetes : A 24-Week , Randomized , Double-Blind , Placebo-Controlled Trial
RESEARCH DESIGN AND METHODS Patients with HbA1c levels of‡7% to£ 10% (‡53 to£86mmol/mol) while receiving metformin (‡1,500 mg/day) were randomized and treated with once-daily treatment with empagliflozin 10mg (n = 217), empagliflozin 25 mg (n = 213), or placebo (n = 207) for 24 weeks. The primary end point was the change in HbA1c level from baseline at week 24. Key secondary end points were changes from baseline in weight and mean daily glucose (MDG) at week 24.